The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
In kidney transplant patients atherosclerosis process is accelerated even in asymptomatic
patients. This is mainly the consequence of immunosuppressive therapy. Dyslipidemia is
treated with statins in low doses only as high doses can lead to rhabdomyolysis and are
therefore contraindicated. As second lipid lowering agent most commonly ezetimibe is used.
The investigators hypothesise that ezetimibe as a second lipid lowering drug in kidney
transplant patients lowers LDL cholesterol for additional 10 per cent.